Testing two drugs, tucatinib and T-DM1, for HER2-positive cancer that has spread to the brain
Original title: A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a phase 2 trial, a middle stage test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether two drugs used together can help control cancer that has spread to the brain.
Who this trial is for. This trial is for people with a HER2-positive solid tumor that has spread to other parts of the body, including the brain. It tests two drugs given together, tucatinib and ado-trastuzumab emtansine, also called T-DM1.
Where it stands. There are no results yet. The trial is measuring whether these two drugs can help control tumors that have spread to the brain. That answer is not in yet.
What this means, and what it doesn't
What it could mean: For someone with HER2-positive cancer that has reached the brain, this is one more option being looked at. If that sounds like your situation, you could ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean the drug pair works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped. And it is not a promise of a cure.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.